8-SUBSTITUTED O-6-BENZYLGUANINE, SUBSTITUTED 6(4)-(BENZYLOXY)PYRIMIDINE, AND RELATED DERIVATIVES AS INACTIVATORS OF HUMAN O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE
My. Chae et al., 8-SUBSTITUTED O-6-BENZYLGUANINE, SUBSTITUTED 6(4)-(BENZYLOXY)PYRIMIDINE, AND RELATED DERIVATIVES AS INACTIVATORS OF HUMAN O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE, Journal of medicinal chemistry, 38(2), 1995, pp. 359-365
Several 8-substituted O-6-benzylguanines, 2- and/or 8-substituted 6-(b
enzyloxy)purines, substituted 6(4)-(benzyloxy)pyrimidines, and a 6-(be
nzyloxy)-s-triazine were tested for their ability to inactivate the hu
man DNA repair protein, O-6-alkylguanine-DNA alkyltransferase (AGT, al
kyltransferase). Two types of compounds were identified as being signi
ficantly more-effective than O-6-benzylguanine (the prototype low mole
cular weight inactivator) at inactivating AGT in human HT29 colon tumo
r cell extracts. These were 8-substituted O-6-benzylguanines bearing e
lectron-withdrawing groups at the 8-position (e.g. 8-aza-O-6-benzylgua
nine and O-6-benzyl-8-bromoguanine) and 5-substituted 2,4-diamino-6-(b
enzyloxy)pyrimidines bearing electron-withdrawing groups at the 5-posi
tion (e.g; 2,4-diamino-6-(benzyloxy)-5-nitroso- and 2,4-diamino-(benzy
loxy)-5-nitropyrimidine). The latter derivatives were also more effect
ive than O-6-benzylguanine at inactivating AGT in intact HT29 colon tu
mor cells. Provided these types of purines and pyrimidines do not exhi
bit undesirable toxicity, they may be superior to O-6-benzylguanine as
chemotherapeutic adjuvants for enhancing the effectiveness of antitum
or drugs for which the mechanism of action involves modification of th
e O-6-position of DNA guanine residues.